Meeting
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Single-center experience with nivolumab in pretreated patients with non-small cell lung cancer (NSCLC).
Authors
Bernardo Leon Rapoport
The Medical Oncology Centre of Rosebank, Johannesburg, South Africa
Bernardo Leon Rapoport, Teresa Smit, Ronwyn van Eeden
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Biomarkers and Inflammatory Signatures,Humoral Immunity for Diagnosis and Therapy,Immune Checkpoints and Stimulatory Receptors,Modulating Innate Immunity,Therapies Targeting T cells
Sub Track
Clinical Trials
Citation
J Clin Oncol 35, 2017 (suppl 7S; abstract 90)
DOI
10.1200/JCO.2017.35.7_suppl.90
Abstract #
90
Poster Bd #
D9
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.
First Author: Jacob Sands
Poster
2017 ASCO Annual Meeting
EA5142 adjuvant nivolumab in resected lung cancers (ANVIL): The newest study in the ALCHEMIST platform.
First Author: Jamie E. Chaft
First Author: Jamie E. Chaft
Poster
2021 ASCO Annual Meeting
The role of chemotherapy plus immune checkpoint inhibitors in oncogenic driven non-small cell lung cancer: A University of California Lung Cancer Consortium retrospective study.
First Author: Karen Kelly